CA2224721A1 - Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives - Google Patents

Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives Download PDF

Info

Publication number
CA2224721A1
CA2224721A1 CA002224721A CA2224721A CA2224721A1 CA 2224721 A1 CA2224721 A1 CA 2224721A1 CA 002224721 A CA002224721 A CA 002224721A CA 2224721 A CA2224721 A CA 2224721A CA 2224721 A1 CA2224721 A1 CA 2224721A1
Authority
CA
Canada
Prior art keywords
benzyloxycarbonyl
ketone
leucyl
phenylalanine
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224721A
Other languages
English (en)
Inventor
Matthew S. Miller
Irennegbe K. Osifo
Todd L. Graybill
Roland E. Dolle
Alex L. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Sanofi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pharmaceuticals Inc filed Critical Sanofi Pharmaceuticals Inc
Priority to PCT/US1995/007463 priority Critical patent/WO1996041638A1/fr
Priority to CA002224721A priority patent/CA2224721A1/fr
Priority to EP95922312A priority patent/EP0840614A1/fr
Priority to AU27043/95A priority patent/AU2704395A/en
Publication of CA2224721A1 publication Critical patent/CA2224721A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux analogues d'acides aminés, et un de leurs sels pharmacologiquement acceptable, de formule (I): Z-A¿3?-A¿2?-A¿1?-Q, dans laquelle Z représente H ou un groupe de protection; A¿3? et A¿2? représentent indépendemment valine, leucine, alanine, isoleucine, phénylalnine, tyrosine, glycine, 2-arylglycine, toutes éventuellement protégées, et présentant une stéréochimie <u>D</u> ou <u>L</u> ou une liaison chimique; A¿1? représente valine, leucine, isoleucine, alanine, phénylalnine, tyrosine, 2-phényl-glycine, 2-phénéthyl-glycine, 2-aryl-glycine, toutes éventuellement protégées; Q représente H, CH¿2?OCOL, CH¿2?OL, CH¿2?SL, CH¿2?X, NHNHCOCH¿2?OCOL, NHNHCOCH¿2?OL, NHNHCOCH¿2?SL, où L représente aryle ou hétéroaryle éventuellement substitués; et X représente CI, Br ou F.
CA002224721A 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives Abandoned CA2224721A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US1995/007463 WO1996041638A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
CA002224721A CA2224721A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
EP95922312A EP0840614A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
AU27043/95A AU2704395A (en) 1995-06-13 1995-06-13 Calpain inhibitors for the treatment of neurodegenerative di seases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/007463 WO1996041638A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
CA002224721A CA2224721A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
CA2224721A1 true CA2224721A1 (fr) 1996-12-27

Family

ID=4161896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224721A Abandoned CA2224721A1 (fr) 1995-06-13 1995-06-13 Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives

Country Status (4)

Country Link
EP (1) EP0840614A1 (fr)
AU (1) AU2704395A (fr)
CA (1) CA2224721A1 (fr)
WO (1) WO1996041638A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038990A1 (fr) * 1997-03-07 1998-09-11 Hoechst Marion Roussel, Inc. Methode de traitement d'un trauma associe a des lesions du cerveau, de la moelle epiniere ou de nerfs peripheriques au moyen de carbobenzyloxy phenylalaninals di- et tri-pepetidiques n-proteges
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6506733B1 (en) 1999-03-15 2003-01-14 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
DE10105038B4 (de) 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105040A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105039A1 (de) * 2001-02-05 2002-08-08 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
KR20050044497A (ko) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. 올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
ES2219187B1 (es) * 2003-05-14 2006-02-16 Consejo Sup. Investig. Cientificas Inhibidores de calpaina.
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
WO2009118375A2 (fr) 2008-03-26 2009-10-01 Novozymes A/S Compositions stabilisées d’enzymes liquides
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
EP4218829A3 (fr) 2013-03-15 2023-08-16 The Board of Trustees of the Leland Stanford Junior University Composés de sonde basée sur l'activité, compositions et méthodes d'utilisation
AU2017382460A1 (en) 2016-12-23 2019-05-02 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3601261A4 (fr) 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University Agents de contraste activés par une protéase pour l'imagerie in vivo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110661A (en) * 1980-02-04 1981-09-01 Ajinomoto Co Inc Preparation of n-benzyloxycarbonyl-l-aspartic acid
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH04273826A (ja) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc 抗ｒｓウイルス剤

Also Published As

Publication number Publication date
EP0840614A1 (fr) 1998-05-13
WO1996041638A1 (fr) 1996-12-27
AU2704395A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
CA2224721A1 (fr) Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
CA1331614C (fr) Derives acyl substitues d&#39;acides 1,2,3,4-tetrahydroisoquinoline-3-carboxyliques
US4757050A (en) Ureido renin inhibitors
CA1282549C (fr) Inhibiteurs de l&#39;aminocarbonyl resine
AU685465B2 (en) New peptides derivatives
AU759492B2 (en) Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
US4996358A (en) Hydroxylamine bearing amino acid derivatives as collagenase inhibitors
US5436229A (en) Bisulfite adducts of arginine aldehydes
CA1341029C (fr) Inhibiteurs de la peptidase
JPS60252495A (ja) スタチンまたはその誘導体を含有するレニン阻害剤
HU204847B (en) Process for producing new peptidase inhibitors
WO1989007610A1 (fr) INHIBITEUR DE RENINE CONTENANT DES AMINOACIDES AVEC UN HETEROATOME alpha
HU204284B (en) Process for producing peptide derivatives containing oxa- or aza-cyclostatine
WO1993025574A1 (fr) Inhibiteurs d&#39;angiotensine i-chymase(s), comprenant la chymase cardiaque humaine
JPH04211095A (ja) 新規ジペプチド、その製造方法及び薬剤におけるレニン阻害剤としてのその使用
US4820691A (en) Amino acid 1,2-diketo derivatives as renin inhibitors
US5852051A (en) Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals
US5442044A (en) Orally active renin inhibitors
CZ145598A3 (cs) Merkaptoalkylpeptidylová sloučenina, její použití pro výrobu přípravku pro léčení nebo prevenci stavu souvisejícího s metalloproteinázou nebo TNF alfa a farmaceutický přípravek ji obsahující
CA2126687A1 (fr) Derives de substitution peptidyliques renfermant de l&#39;acide phosphonique, agents antidegeneratifs
NZ211600A (en) Substituted ureido-amino and -imino acid derivatives and pharmaceutical compositions
US4552866A (en) Use of diamino alcohols as analgesic agents
US5242903A (en) Renin inhibitors
US4670541A (en) Use of diamino alcohols as analgesic agents
US5922697A (en) Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins

Legal Events

Date Code Title Description
FZDE Discontinued